ArticleNature chemical biology2010
Grand challenge commentary: Synthetic immunology to engineer human immunity.
Article in Nature chemical biology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease.ACS chemical biology · 2012Pooled it
- Nanobodies and their derivatives: pioneering the future of cancer immunotherapy.Cell communication and signaling : CCS · 2025Review
- Recruiting the Immune System against Pathogenic Bacteria Using High-Affinity Chimeric Tags.Bioconjugate chemistry · 2024Article
- Emerging drug design strategies in anti-influenza drug discovery.Acta pharmaceutica Sinica. B · 2023Review
- Antibody Recognition of Cancer Cells via Glycan Surface Engineering.Chembiochem : a European journal of chemical biology · 2022Article
- Engineered Th17 Cell Differentiation Using a Photoactivatable Immune Modulator.Journal of the American Chemical Society · 2020Article
- Multifunctional Glycoconjugates for Recruiting Natural Antibodies against Cancer Cells.Chemistry (Weinheim an der Bergstrasse, Germany) · 2019Article
- Synthetic Immunology: Hacking Immune Cells to Expand Their Therapeutic Capabilities.Annual review of immunology · 2017Review
- Glycomaterials for probing host-pathogen interactions and the immune response.Experimental biology and medicine (Maywood, N.J.) · 2016Review
- Bioorthogonal Catalysis: A General Method To Evaluate Metal-Catalyzed Reactions in Real Time in Living Systems Using a Cellular Luciferase Reporter System.Bioconjugate chemistry · 2016Article
- Multi-target drugs to address multiple checkpoints in complex inflammatory pathologies: evolutionary cues for novel "first-in-class" anti-inflammatory drug candidates: a reviewer's perspective.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2015Review
- Chemically synthesized molecules with the targeting and effector functions of antibodies.Journal of the American Chemical Society · 2014Article
- Stimulation of innate immune cells by light-activated TLR7/8 agonists.Journal of the American Chemical Society · 2014Article
- Exploring binding and effector functions of natural human antibodies using synthetic immunomodulators.ACS chemical biology · 2013Article
- Reprogramming urokinase into an antibody-recruiting anticancer agent.ACS chemical biology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rationally designing new strategies to control the human immune response stands as a key challenge for the scientific community. Chemical biologists have the opportunity to address specific issues in this area that have important implications for both basic science and clinical medicine.
Indexed as
Identifiers
21079593What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.